drugset / Trial / NCT06380153

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

NCT06380153

Phase 1 Completed 26 enrolled Ganzhou Hemay Pharmaceutical Co., Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study was to evaluate the pharmacokinetics of Hemay005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication regimens for patients with renal impairment.

Timeline

Start
2024-05-07
Primary completion
2025-04-16
Completion
2025-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject MUFEMILAST Small molecule 60 mg Oral

Indications